MedTrace Logo

Safety and Efficacy of MCC-257 in the Treatment of Diabetic Polyneuropathy

NCT00307749 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 420

Last updated 2007-12-28

No results posted yet for this study

Summary

The primary objectives of the study are to evaluate the efficacy and safety of three doses of MCC-257 in patients with mild to moderate diabetic polyneuropathy

Conditions

  • Diabetic Polyneuropathy

Interventions

DRUG

Placebo

once daily for 24 weeks

DRUG

MCC-257

20mg, once daily for 24 weeks

DRUG

MCC-257

40mg, once daily for 24 weeks

DRUG

MCC-257

80mg, once daily for 24 weeks

Sponsors & Collaborators

  • Mitsubishi Tanabe Pharma Corporation

    lead INDUSTRY

Principal Investigators

  • Professor · Information at Mitsubishi Pharma America

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Completion
2007-08-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00307749 on ClinicalTrials.gov